Danaher is back in focus as analysts cluster around higher price targets, with several recent updates now sitting in the US$260 to US$275 range. These moves line up with research that highlights the company's 2027 core growth framing, Q3 2026 trends, and how execution could feed through to margins, organic growth, and Danaher's P/E multiple over time. Read on to see what is driving the shift in the analyst narrative and how you can track the story from here.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Several firms including Goldman Sachs, JPMorgan, Citi, BofA, TD Cowen, Barclays, Stifel and UBS have lifted Danaher price targets into roughly the US$250 to US$275 range, which clusters around higher valuation expectations for the stock.
-
BofA and Citi point to Danaher management's initial 2027 core revenue growth framing of 4% to 5% excluding respiratory as a key anchor for long term growth, with BofA explicitly flagging potential upside to that range.
-
TD Cowen, Stifel and RBC Capital highlight healthier bioprocessing and life sciences trends, along with continued recovery in diagnostics, as factors that could support organic growth and help justify higher P/E multiples over time.
-
Barclays and Baird updated models after Danaher's Q3 report and reference "upside drivers" and a constructive set up, which they link to the potential for earnings outperformance against near term expectations.
🐻 Bearish Takeaways
-
Stifel describes Danaher as a "show me" story and points to anticipated respiratory headwinds into Q4, which keeps execution risk in focus and places more pressure on the 2026 exit rate to support current valuation.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 1 risk for Danaher. See which could impact your investment.
How This Changes the Fair Value For Danaher
-
Our fair value estimate for Danaher has moved from about US$244.14 to roughly US$259.90 based on the refreshed model.
-
The long-term revenue growth input has shifted from around 8.06% to about 7.69%.
-
The profit margin assumption has adjusted from roughly 19.34% to about 19.88%.
-
The assumed future P/E multiple has moved from about 35.1x to roughly 36.2x.
-
The discount rate has changed slightly from 8.36% to about 8.37%.
Never Miss an Update: Follow The Narrative
Narratives connect Danaher's business story to a set of financial assumptions and a fair value framework. They refresh as new earnings, guidance, and industry data come through so you can see how the story is evolving in real time.
Head over to the Simply Wall St Community and follow the Narrative on Danaher to stay up to date on:
-
How biologics, single use bioprocessing equipment, and AI linked life sciences demand are feeding into expectations for sustained core revenue growth at Danaher.
-
The role of higher recurring consumables and software revenue in Diagnostics, including trends in non respiratory molecular assays and growth markets such as China and other high growth regions.
-
Key risks around trade frictions, pricing and reimbursement pressure in China, and softer respiratory testing that could challenge the current growth and earnings outlook.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DHR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
